Strategies for improving long-term survival in patients with ESRD

Journal of the American Society of Nephrology

Volumn 16, Issue 11 SUPPL. 2, 2005, Pages

  Nolan, Charles R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLESTILAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; SEVELAMER; PHOSPHATE BINDING PROTEIN;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COST MINIMIZATION ANALYSIS; DIALYSIS; DRUG COST; DRUG USE; HEALTH CARE COST; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MINERAL METABOLISM; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; CHRONIC KIDNEY FAILURE; ECONOMICS; KIDNEY TRANSPLANTATION; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PHOSPHATE-BINDING PROTEINS; RISK FACTORS; SURVIVAL RATE;

EID: 33644840836     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005060662     Document Type: Review

References (65)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spi0.000.0nosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
2. Szczech LA, Lazar IL: Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int Suppl 90: S3-S7, 2004
3. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35: S117-S131, 2000
4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
6. Beadenkopf WG, Daoud AS, Love BM: Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. AJR Radium Ther Nucl Med 92: 865-871, 1964
7. London GM, Marchais SJ, Guerin AP, Metivier F: Impairment of arterial function in chronic renal disease: Prognostic impact and therapeutic approach. Nephrol Dial Transplant 17[Suppl 11]: 13-15, 2002
8. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
9. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998
10. Huting J: Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 105: 383-388, 1994
11. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 11: 778-783, 2000
12. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799-805, 1998
13. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N: Vascular calcification in chronic kidney disease. Am J Kidney Dis 43: 572-579, 2004
14. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002
15. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
16. Schinke T, McKee MD, Kiviranta R, Karsenty G: Molecular determinants of arterial calcification. Ann Med 30: 538-541, 1998
17. Proudfoot D, Shanahan CM: Biology of calcification in vascular cells: Intima versus media. Herz 26: 245-251, 2001
18. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
19. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
20. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001
21. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Tourna T, Takishita S: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8: 54-58, 2004
22. Levey AS: Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start? Am J Kidney Dis 32: S5-S13, 1998
23. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362, 2000
24. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 54: 561-569, 1998
25. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61: 1887-1893, 2002
26. Kalantar-Zadeh K, Kilpatrick RD, Kopple JD: Reverse epidemiology of blood pressure in dialysis patients. Kidney Int 67: 2067, 2005
27. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002
28. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002
29. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
30. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
31. Block GA: Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 54: 318-324, 2000
32. Block GA, Klasser PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
33. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 38: S34-S37, 2001
34. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 2511-2516, 2001
35. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
36. Al Aly Z, Edwards JC: Vascular biology in uremia: Insights into novel mechanisms of vascular injury. Adv Chronic Kidney Dis 11: 310-318, 2004
37. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106: 100-105, 2002
38. Brancaccio D, Tetta C, Gallieni M, Panichi V: Inflammation CRP, calcium overload and a high calcium-phosphate product: A "liaison dangereuse." Nephrol Dial Transplant 17: 201-203, 2002
39. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
40. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001
41. Pozzoni P, Pozzi M, Del Vecchio L, Locatelli F: Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients. Semin Nephrol 24: 417-422, 2004
42. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
43. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 1489-1496, 2004
44. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23: 307-314, 2003
45. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339: 1972-1978, 1998
46. Achenbach S, Ropers D, Fohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation 106: 1077-1082, 2002
47. Nitta K, Akiba T, Nihei H: Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 2156, 2004
48. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36: S24-S30, 2000
49. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974
50. Ritz E, McClellan WM: Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol 15: 513-516, 2004
51. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13: 180-193, 1989
52. Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291-1295, 2003
53. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730, 1999
54. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B: Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4: 1662-1668, 2004
55. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
56. Klarman HE: Approaches to moderating the increases in medical care costs. Med Care 7: 175-190, 1969
57. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N: A study of the quality of life and cost-utility of renal transplantation. Kidney Int 50: 235-242, 1996
58. Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation-A prospective study. Transplantation 54: 656-660, 1992
59. Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312: 553-559, 1985
60. Cleemput I, Kesteloot K, Vanrenterghem Y, De Geest S: The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 22: 1217-1234, 2004
61. Karlberg I, Nyberg G: Cost-effectiveness studies of renal transplantation. Int J Technol Assess Health Care 11: 611-622, 1995
62. Eggers P: Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 12: 284-289, 1992
63. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914-1926, 2004
64. Uribarri J: K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: Some therapeutic implications. Semin Dial 17: 349-350, 2004
65. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239-1247, 2004